Highlights AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2024-12-10 EST			5-day change	1st Jan Change
175.67 ^USD	-0.51%		-3.21%	+13.36%

12-09	AbbVie Reports Durable Results from Mono, Combo Therapy for Blood Cancer	MT
12-09	Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AbbVie Reports Durable Results from Mono, Combo Therapy for Blood Cancer	12-09	MT
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma	12-09	CI
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- Update	12-09	DJ
Correction to AbbVie Tavapadon Phase 3 Study Article	12-09	DJ
AbbVie's Phase 3 Trial of Tavapadon for Parkinson's Disease Meets Endpoints	12-09	MT
AbbVie's Tavapadon Hits Key Goals in Second Phase 3 Parkinson's Study	12-09	DJ
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease	12-09	CI
AbbVie Inc. Announces Updated Results from the Phase 1b/2 EPCORE® NHL-2 Trial Evaluating Fixed-Duration Investigational Epcoritamab	12-07	CI
Daiwa Securities Downgrades AbbVie to Neutral From Outperform, Adjusts Price Target to $180 From $210	12-05	MT
AbbVie Shares Rise as Leerink Partners Upgrades Stock	11-22	MT
Wells Fargo Adjusts Price Target on AbbVie to $195 From $205, Maintains Overweight Rating	11-18	MT
Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA	11-18	MT
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer	11-18	DJ
AbbVie Says Elahere Gets Approval From European Commission as Ovarian Cancer Treatment	11-18	MT
Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer	11-18	CI
Redburn Atlantic Adjusts AbbVie's Price Target to $216 From $215, Keeps Buy Rating	11-15	MT
Deutsche Bank Adjusts Price Target on AbbVie to $177 From $180, Keeps Hold Rating	11-14	MT
JPMorgan Adjusts Price Target on AbbVie to $200 From $210, Keeps Overweight Rating	11-13	MT
UBS Lowers Price Target on AbbVie to $181 From $200, Keeps Neutral Rating	11-12	MT
Goldman Sachs Cuts AbbVie Price Target to $205 From $210, Maintains Buy Rating	11-12	MT
Berenberg Adjusts Price Target on AbbVie to $165 From $170, Maintains Hold Rating	11-12	MT
Morgan Stanley Adjusts Price Target on AbbVie to $224 From $231, Maintains Overweight Rating	11-12	MT
BMO Capital Adjusts Price Target on AbbVie to $208 From $228, Maintains Outperform Rating	11-12	MT
Hungary's Richter CEO reiterates 2024 guidance after strong third quarter	11-12	RE
Health Care Down as AbbVie, Humana Weigh -- Health Care Roundup	11-11	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Highlights

Filters